MavriX Bio Secures FDA Rare Pediatric Disease Designation for MVX-220, Targeting Angelman Syndrome #United_States #Middleton #Angelman_Syndrome #MVX-220 #MavriX_Bio
@newsen.bsky.social@newsen.bsky.social
@newsen.bsky.socialMavriX Bio Secures FDA Rare Pediatric Disease Designation for MVX-220, Targeting Angelman Syndrome #United_States #Middleton #Angelman_Syndrome #MVX-220 #MavriX_Bio